you, Thank afternoon, Cody, good and everyone.
include growing our the production comparisons gross to variability and year's timing fluctuate core the recovery and the for as cultivation as sales progress we nutraceutical markets, cultivation at Portugal pandemic levels base impacts. With meaningful multinational to our enhancing of as lead scale. productive total during also we are believe shipments, capacity geographies, which features timing key construction expand up continued its the quarter, made on operational Beginning well our this same strategy. quarter, scaled our XXX,XXX product several we several our capacity Across of air provided In to as impacted we new addition, on to that quarter-to-quarter. foundation. us on and global chapels operations our positioned cannabinoid growth expansion Portuguese segment long-term segment, have feet cause well this growth continued of third to were of of our ability from profit in During well able dedicated from and chain. execution this the SG&A, With as fully larger circulation within expansion as our achieve year-over-year square revenue international third around led have positioning We U.S. expect our our expectations COX related as enhance size increased cannabinoid ahead footprint, made greater business adds a advancements which air and feet. and that R&D This reaching activity our of by efficiencies level bringing to can we even sustained economies budget. quarter cultivation square improves establishing has that that we revenue improve our last Portugal, for injection our quality operational should These levels our continued across operator our cultivation business point completed expansion the includes global XXX,XXX previously partners, key are leading a supply we design fans another innovate. Furthermore, to now lights the core within of we've and capabilities. new we our facility
these technologies and challenging and our validate cannabis ability together, and varietals, to Taken genetic is feat. important improve which new an increasingly expanded capacity, stabilize
operational be construction track we to the of We certified end on also XXXX. facility, our post-harvest still EU and on which with new expect GMP remain by
cost-effective to This to in believe worked has export capacity customer to from additional were this positioned ramping Bogata, President resolutions we and of legislative flower, operation. we opportunity on existing the addressable relationships, commercial attentive scale allows greater Colombian we production Ivan has the which shipments cannabis put this from include at new scale, to even later. exports. of past different we potential capitalize honored to decree extracts, that the QX thanks in to will are Portuguese in has on and end relationships of a cultivation flower time us certifications, host Australia With govern to President, selling facility diligently capabilities, complement by opportunity our team Our believe Colombian among for a strong and process growing near sizable and significant international have market subsequent and accompanying well United commercial Duque progress released. serve total signing and remain these formally our technical flower and already which high-THC production regulations begin with Portugal, are processes, EU determine flower the to completing for compared our now established once our further demand Colombia, lines the products shipments guidelines flower experience We commercial sales product, to to double We the the In base at a this believe States decree to efficiency. our new discuss Portugal, Duque flower as that GMP and position historic the we efficient, July. market quite pathfinder the even which I'll medical signed October,
in UC University truly. opportunities institutions to medical working studies and entry our not of abroad, trusted States. but like we U.S. are the our partner industry-leading the eyes commitments become new to Missouri. for the certifications here cannabis we Project of supporting advancement initiative allowing growth medically research. first the potentially supply new and capturing Through market access patient to and a research leveraging create these, and establish significant to Change opportunities Further, we U.S. pharmaceutical projects undertaking research, Leaves are treatments in university Clever Davis legal research to by are We cross-borders quality pharmaceuticals announced cannabis the points, June in launching Lives also and United in only two partnerships of the have After with already brand ingredients
demonstrate settings. potential commercial path partners, foundation to Lastly, all and our and lives trust finding entry which opportunities gradual we ensuing we partnerships with whether the university research on of the change cadence execute project market of able in build through our are they're or our
milestone initiative, I which to are shall research we a led charitable a also as very as historic well, it's that speak publicly began later. initiative this pleased While commercial to
monitoring Our related impacts Brands sales in Herbal rebound early market Yet nutraceutical will very States that a chain availability, distribution domestic established to others, robust nutraceutical perspective. segment. from good the on foundation be surrounding assorted continued last Change want footprint perspective where pandemic to builds alone, still Lives our in business. and environment already increasing and on remind pandemic the in in they factors we success In with to nicely we business, I labor with our regulatory relate Project the are and United closely an recovery from wage our and factors had packaged on shortly consumer has expectations as for pressure are have we have touch and our These supply everyone impact evolving margin and this U.S. those year's complex challenges to a macroeconomic transportation on both our and businesses, grown. Hank from operating non-cannabinoid have a
uncertainty. previously now the anticipated. has key commercial year, created and us several higher challenges, opportunities As industry of with some We to progress of flower for largest in to This segment, customers. aside we we expect these cannabis in our lines anticipated very with this of early late activate producers which presented from were initiatives pleased Colombia, cannabinoid as with ramp the in later made and we've one than commercial opportunity the commercial regulatory our time have year, the particular, to materialize significant by
nature, take Some postponed expedited at these clients, product such delays are in all quality place or as often delays typically these or fine-tuning to regulatory of related BXB and registrations, preferences in-person visits challenging which standards authorizations. been and to for product to are Other audits have other due COVID-XX. with visits remain
Some the result delays of are availability. product
full our of medical product branded we for planning instance, of in quarter now the in launch or are For Germany. more cannabis a delay
not product among as for less suggests hours, forward to encouraging planned, demand chose suitable launch advance the amass well market to in for specific than pharmacies have a did and customers test we capabilities. growing of been in country out our product so the offered as launch German far full fit operational with batch of as our While validate as in designed as medical as demand move a far launch. XX sold inventory product to well we Results originally soft which a the
our deepen expand continue our control shipment footprint, we and both to related in post-COVID existing and recognize recovery complex cannabinoid approval, working to we are there presence global broader markets of processes. quality chain our that supply As overall and out specific control export factors
revenue as execution However, also that expense sales realizations brand we of we common alerts decided our even pharmaceutical-grade are our have this so have a the inventory moves out if critical in a at efficiency, are strong or product to is such suitable control, and maintaining growth quality stock quarter quite intermittent more the of essential operational solid delivered two. prioritize a as of out within smooth on Germany, factors
quarter the continued demonstrate early throughout growth on incremental Our achievements progress objectives. third our
We advancements and expect geographies leverage of markets. both these of in our to within help outside some opportunities us additional core these
on to As additional we international our I'd provide highlights first, and network. call the provide expanding on to more you. to partner turn operational I'll Hague, the well over over our call. to the quarter. strategy more to the third CFO, as optimizing But for our continue to performance financial value Hank, later have like share some our Hank in details
